Navigation Links
Psoriasis in Medical Technology
... with inflamed, scaly, red patches of skin psoriasis and psoriasis nail involvement. Symptoms may include stiffness ... feet, lower back and neck are commonly affected. psoriasis affects an estimated two to three percent of the ...
... company in New Jersey that's done the same for psoriasis sufferers of all ages." Mr. Steele is ... associated with their non-prescription, psoriasis medicine PSORENT(R) psoriasis topical solution. Earlier this week, ...
... than three percent Body Surface Area (BSA) psoriasis skin involvement at baseline (n=296) were ... with inflamed, scaly, red patches of skin psoriasis and psoriasis nail involvement. Symptoms may include stiffness ...
... from a study of sequential treatment of plaque psoriasis using Clobex (R) (clobetasol propionate) Spray ... indicate that sequential treatment of plaque psoriasis with Clobex Spray followed by Vectical Ointment is effective in managing plaque psoriasis over a 12-week period. Additionally, the interim ...
... surface, the thick, red, scaly, itchy plaques of psoriasis -- which have been shown to have a significant ... However, a growing body of research suggests that psoriasis patients are at an increased risk of developing ... disease and diabetes, particularly when their psoriasis is severe. Speaking today at the 67th Annual ...
... the first biologic treatment indicated for severe psoriasis in children and adolescents. Enbrel is currently ... for the treatment of moderate-to-severe plaque psoriasis in adults, as well as for ankylosing spondylitis, ... similar for Enbrel and placebo. Impact of psoriasis Across Europe, 5.1 million people are ...
... Treats Adult Patients with Moderate to Severe psoriasis Regardless of Age, Duration of Disease, ... PARIS, Sept. 18 /PRNewswire-FirstCall/ -- More psoriasis patients achieve efficacy when they receive ... Every Other Week in Moderate to Severe psoriasis Trial) and the period of open-label treatment ...
... Clinical, Centocor R&D. "For many patients, psoriasis is a serious disease, and they are in need of ... the drug are made by the FDA. About Psoriasis psoriasis is a chronic, immune-mediated disease, caused by ... Europeans. Nearly one-quarter of people with psoriasis have cases that are considered moderate to ....
... with psoriasis commonly have similar areas of psoriasis on their left and right, or front and back sides. ... trial, 35 patients treated one of their areas of psoriasis with AN2728 ointment, and a matching area on ... approximately 10 million people worldwide, psoriasis is an inflammation of the skin caused by a ...
... showed patients with moderate to severe plaque psoriasis receiving REMICADE(R) (infliximab) achieved ... clinical trials evaluated, the Study of psoriasis with Infliximab [REMICADE] Induction Therapy ... (EXPRESS), and the Evaluation of Infliximab for psoriasis in a [REMICADE] Efficacy and Safety Study ...
... patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy ... disease in 2007. "The approval of HUMIRA for psoriasis is welcome news for people living with this ... Pam Field, acting president and CEO, National psoriasis Foundation. "We are pleased to let people ...
... for patients with rheumatoid arthritis (RA), psoriasis and other immune disorders. In preclinical ... swelling. It has also shown efficacy in models of psoriasis and transplant rejection. This is Rigel's fourth ... debilitating and degenerative autoimmune disease. psoriasis affects approximately 7.5 million in the U.S. and ...
... Europeans. Nearly one-quarter of people with psoriasis have cases that are considered moderate to ... who achieved at least a 75 percent reduction in psoriasis as measured by the psoriasis Area and Severity Index (PASI 75). "We are very ...
... disease (as measured by a 75 percent reduction in psoriasis Area and Severity Index [PASI 75] in patients with baseline body surface area with psoriasis of at least three percent, and the Nail psoriasis Severity Index [NAPSI]). Golimumab, Centocor ....
... of patients with moderate to severe plaque psoriasis receiving two doses of ustekinumab (CNTO 1275) achieved at least a 75 percent reduction in psoriasis at week 12, the primary endpoint of the study, as measured by the psoriasis Area and Severity Index (PASI 75). ...
... (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and psoriasis (PsO). The safety and efficacy of REMICADE have been well established in ... Crohn's disease, ankylosing spondylitis, psoriatic arthritis or plaque psoriasis for a long time, particularly those with highly active disease may be more ...
... developed Psorent to answer patient needs for a non-prescription topical psoriasis therapy that offers a different experience from traditional coal tar ... this study validates our success in creating this new-generation topical psoriasis therapy that offers clinical efficacy in an aesthetically pleasing ...
... commercialization including forodesine HCl in oncology, BCX-4208 in psoriasis and peramivir in seasonal and life-threatening influenza. BioCryst is ... (CTCL) may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization ...
... commercialization including forodesine HCl in oncology, BCX-4208 in psoriasis and peramivir in seasonal and life-threatening influenza. BioCryst is ... (CTCL) may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization ...
... expects to begin enrollment of patients with mild-to-moderate plaque psoriasis in a Phase 2 trial in the third quarter of 2008, as originally planned. ... inflammation related to oxidative stress. It currently plans a program in psoriasis with its lead compound. The Company is developing a clinical diagnostic ...
... (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and psoriasis (PsO). The safety and efficacy of REMICADE have been well established in ... Crohn's disease, ankylosing spondylitis, psoriatic arthritis or plaque psoriasis for a long time, particularly those with highly active disease may be more ...
... (CD), rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and psoriasis (PsO). The safety and efficacy of REMICADE have been well established in clinical trials over the past 16 years and through commercial experience ...
... in Phase 1 as a potential treatment for dyslipidemia. Becocalcidiol, a novel Vitamin D analogue, is in Phase 2 clinical trials for the treatment of psoriasis through QuatRx's partner, Galderma. QuatRx's preclinical program is designed to address sex steroid dependent diseases through inhibition of ...
... currently conducting Phase 2 clinical trials of its proprietary drugs PV-10 as a therapy for metastatic melanoma and PH-10 as a topical treatment for psoriasis and atopic dermatitis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov . ...
... research resources are related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), rheumatoid arthritis, multiple sclerosis, psoriasis and dermatology in general. Almirall is currently present in over 70 countries with direct presence in Europe and Latin America through 11 ...
... with diastolic heart failure; and - the Phase 2 trial of a topical formulation of SYI-2074 for the treatment of chronic, mild-to-moderate plaque psoriasis in adults. Each of these trials will be terminated as promptly as possible. As noted previously, the Company has submitted an application ...
... infertility (Gonal-f(R)), endocrine and cardiometabolic disorders (Glucophage(R), Concor(R), Euthyrox(R), Saizen(R), Serostim(R)), as well as psoriasis (Raptiva(R)). With an annual R&D expenditure of around EUR 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic ...
... infertility (Gonal-f(R)), endocrine and cardiometabolic disorders (Glucophage(R), Concor(R), Euthyrox(R), Saizen(R), Serostim(R)), as well as psoriasis (Raptiva(R)). With an annual R&D expenditure of around EUR 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic ...
... in Phase 1 as a potential treatment for dyslipidemia. Becocalcidiol, a novel Vitamin D analogue, is in Phase 2 clinical trials for the treatment of psoriasis through QuatRx's partner, Galderma. QuatRx's preclinical program is designed to address sex steroid dependent diseases through inhibition of ...
... research resources are related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), rheumatoid arthritis, multiple sclerosis, psoriasis and dermatology in general. Almirall is currently present in over 70 countries with direct presence in Europe and Latin America through 11 ...
... Cancer were instrumental in extending my life," states Mercie Madrid. Another participant, Mike Means, says, "I participated in a clinical trial for psoriasis and my condition improved dramatically." ASPIRE IRB's 10 Ways to Protect Participants' Rights and Maximize Results for Clinical Research 1) ...
... in patients with active ankylosing spondylitis. HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HUMIRA should only be ...
... company in New Jersey that's done the same for psoriasis sufferers of all ages." Mr. Steele is ... associated with their non-prescription, psoriasis medicine PSORENT(R) psoriasis topical solution. Earlier this week, ...
... than three percent Body Surface Area (BSA) psoriasis skin involvement at baseline (n=296) were ... with inflamed, scaly, red patches of skin psoriasis and psoriasis nail involvement. Symptoms may include stiffness ...
... from a study of sequential treatment of plaque psoriasis using Clobex (R) (clobetasol propionate) Spray ... indicate that sequential treatment of plaque psoriasis with Clobex Spray followed by Vectical Ointment is effective in managing plaque psoriasis over a 12-week period. Additionally, the interim ...
... surface, the thick, red, scaly, itchy plaques of psoriasis -- which have been shown to have a significant ... However, a growing body of research suggests that psoriasis patients are at an increased risk of developing ... disease and diabetes, particularly when their psoriasis is severe. Speaking today at the 67th Annual ...
Scientists Unmask Genetic Markers Associated With Psoriasis
... scientists reveal DNA 'hotspots' linked to psoriasis ANN ARBOR, Mich., Jan. 25 ... IL-23 pathway are already targeted by effective psoriasis therapies. Others, like TNFAIP3 and TNIP1, may become targets for the psoriasis treatments of the future." ...Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
... the treatment of chronic, mild-to-moderate plaque psoriasis in adults. The trial is being conducted in three ... to expand the scope of treatment modalities for psoriasis following this trial and look forward to ... can be inhibited by SYI-2074. About psoriasis ...... the first biologic treatment indicated for severe psoriasis in children and adolescents. Enbrel is currently ... for the treatment of moderate-to-severe plaque psoriasis in adults, as well as for ankylosing spondylitis, ... similar for Enbrel and placebo. Impact of psoriasis Across Europe, 5.1 million people are ...
... Treats Adult Patients with Moderate to Severe psoriasis Regardless of Age, Duration of Disease, ... PARIS, Sept. 18 /PRNewswire-FirstCall/ -- More psoriasis patients achieve efficacy when they receive ... Every Other Week in Moderate to Severe psoriasis Trial) and the period of open-label treatment ...
... Clinical, Centocor R&D. "For many patients, psoriasis is a serious disease, and they are in need of ... the drug are made by the FDA. About Psoriasis psoriasis is a chronic, immune-mediated disease, caused by ... Europeans. Nearly one-quarter of people with psoriasis have cases that are considered moderate to ....
... with psoriasis commonly have similar areas of psoriasis on their left and right, or front and back sides. ... trial, 35 patients treated one of their areas of psoriasis with AN2728 ointment, and a matching area on ... approximately 10 million people worldwide, psoriasis is an inflammation of the skin caused by a ...
... showed patients with moderate to severe plaque psoriasis receiving REMICADE(R) (infliximab) achieved ... clinical trials evaluated, the Study of psoriasis with Infliximab [REMICADE] Induction Therapy ... (EXPRESS), and the Evaluation of Infliximab for psoriasis in a [REMICADE] Efficacy and Safety Study ...
Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis
... Ustekinumab Maintained Improvement from psoriasis Through One Year SAN ... in the treatment of moderate to severe plaque psoriasis through one year. According to findings presented ... sustained at least a 75 percent improvement in psoriasis through one year, as measured by the ...... patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy ... disease in 2007. "The approval of HUMIRA for psoriasis is welcome news for people living with this ... Pam Field, acting president and CEO, National psoriasis Foundation. "We are pleased to let people ...
... for patients with rheumatoid arthritis (RA), psoriasis and other immune disorders. In preclinical ... swelling. It has also shown efficacy in models of psoriasis and transplant rejection. This is Rigel's fourth ... debilitating and degenerative autoimmune disease. psoriasis affects approximately 7.5 million in the U.S. and ...
Study Linking Increased Risk of Death to Severe Psoriasis a Call to Action
... National psoriasis Foundation urges psoriasis patients to take control of their health, help ... week showing that people with severe psoriasis are likely to have a shorter life expectancy ...... Europeans. Nearly one-quarter of people with psoriasis have cases that are considered moderate to ... who achieved at least a 75 percent reduction in psoriasis as measured by the psoriasis Area and Severity Index (PASI 75). "We are very ...
... disease (as measured by a 75 percent reduction in psoriasis Area and Severity Index [PASI 75] in patients with baseline body surface area with psoriasis of at least three percent, and the Nail psoriasis Severity Index [NAPSI]). Golimumab, Centocor ....
... of patients with moderate to severe plaque psoriasis receiving two doses of ustekinumab (CNTO 1275) achieved at least a 75 percent reduction in psoriasis at week 12, the primary endpoint of the study, as measured by the psoriasis Area and Severity Index (PASI 75). ...
Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
... Study Data Show Patients with Moderate to Severe psoriasis Who Responded to Anti-IL-12/23 ABT-874 after 12 ... who achieved 75 percent improvement in psoriasis signs and symptoms (PASI 75) at 12 weeks stopped ... 90 percent of patients with moderate to severe psoriasis achieved 75 percent improvement ...Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
... in the treatment of moderate to severe plaque psoriasis will be presented for the first time at the 21st ... for the treatment of moderate to severe plaque psoriasis and is being investigated as an ... countries outside of the United States. About psoriasis ...... (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and psoriasis (PsO). The safety and efficacy of REMICADE have been well established in ... Crohn's disease, ankylosing spondylitis, psoriatic arthritis or plaque psoriasis for a long time, particularly those with highly active disease may be more ...
... developed Psorent to answer patient needs for a non-prescription topical psoriasis therapy that offers a different experience from traditional coal tar ... this study validates our success in creating this new-generation topical psoriasis therapy that offers clinical efficacy in an aesthetically pleasing ...
... commercialization including forodesine HCl in oncology, BCX-4208 in psoriasis and peramivir in seasonal and life-threatening influenza. BioCryst is ... (CTCL) may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization ...
... commercialization including forodesine HCl in oncology, BCX-4208 in psoriasis and peramivir in seasonal and life-threatening influenza. BioCryst is ... (CTCL) may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization ...
... expects to begin enrollment of patients with mild-to-moderate plaque psoriasis in a Phase 2 trial in the third quarter of 2008, as originally planned. ... inflammation related to oxidative stress. It currently plans a program in psoriasis with its lead compound. The Company is developing a clinical diagnostic ...
... (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and psoriasis (PsO). The safety and efficacy of REMICADE have been well established in ... Crohn's disease, ankylosing spondylitis, psoriatic arthritis or plaque psoriasis for a long time, particularly those with highly active disease may be more ...
Cytokine PharmaSciences Initiates Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364
... An intravenous formulation of semapimod was shown to have significant anti-inflammatory activity in Phase II clinical trials in Crohn's disease, psoriasis and ERCP-induced pancreatitis. However, that formulation caused dose-limiting local reactions, such as phlebitis. To overcome this problem, the ...... (CD), rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and psoriasis (PsO). The safety and efficacy of REMICADE have been well established in clinical trials over the past 16 years and through commercial experience ...
... in Phase 1 as a potential treatment for dyslipidemia. Becocalcidiol, a novel Vitamin D analogue, is in Phase 2 clinical trials for the treatment of psoriasis through QuatRx's partner, Galderma. QuatRx's preclinical program is designed to address sex steroid dependent diseases through inhibition of ...
... currently conducting Phase 2 clinical trials of its proprietary drugs PV-10 as a therapy for metastatic melanoma and PH-10 as a topical treatment for psoriasis and atopic dermatitis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov . ...
... research resources are related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), rheumatoid arthritis, multiple sclerosis, psoriasis and dermatology in general. Almirall is currently present in over 70 countries with direct presence in Europe and Latin America through 11 ...
Study Finds Family History, Higher Incidence of Sunburns Associated With Rosacea
... as well as explore whether rosacea was predictive of other systemic conditions that might be related -- similar to the link between severe cases of psoriasis and other medical conditions such as diabetes and heart disease." In this case-controlled study that built on the photo study conducted at ...... with diastolic heart failure; and - the Phase 2 trial of a topical formulation of SYI-2074 for the treatment of chronic, mild-to-moderate plaque psoriasis in adults. Each of these trials will be terminated as promptly as possible. As noted previously, the Company has submitted an application ...
... infertility (Gonal-f(R)), endocrine and cardiometabolic disorders (Glucophage(R), Concor(R), Euthyrox(R), Saizen(R), Serostim(R)), as well as psoriasis (Raptiva(R)). With an annual R&D expenditure of around EUR 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic ...
... infertility (Gonal-f(R)), endocrine and cardiometabolic disorders (Glucophage(R), Concor(R), Euthyrox(R), Saizen(R), Serostim(R)), as well as psoriasis (Raptiva(R)). With an annual R&D expenditure of around EUR 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic ...
... in Phase 1 as a potential treatment for dyslipidemia. Becocalcidiol, a novel Vitamin D analogue, is in Phase 2 clinical trials for the treatment of psoriasis through QuatRx's partner, Galderma. QuatRx's preclinical program is designed to address sex steroid dependent diseases through inhibition of ...
... research resources are related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), rheumatoid arthritis, multiple sclerosis, psoriasis and dermatology in general. Almirall is currently present in over 70 countries with direct presence in Europe and Latin America through 11 ...
... Cancer were instrumental in extending my life," states Mercie Madrid. Another participant, Mike Means, says, "I participated in a clinical trial for psoriasis and my condition improved dramatically." ASPIRE IRB's 10 Ways to Protect Participants' Rights and Maximize Results for Clinical Research 1) ...
... in patients with active ankylosing spondylitis. HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HUMIRA should only be ...
Other ContentsOther Tags
(Date:5/22/2013)... The feared Legionella pneumophila bacteria is responsible ... pneumonia. In order to infect us, this pathogen has ... and go unnoticed in our cells, thus avoiding these ... the Basque biosciences research centre, CIC bioGUNE, in which ... the USA and the National Supercomputation Centre in Barcelona ...
(Date:5/22/2013)... how climate change will affect interactions between species in ... of Animal Ecology . This knowledge, they say, is ... how species are likely to be impacted by rising ... among biologists that climate change is affecting how species ... to have very important consequences for the stability and ...
(Date:5/22/2013)... Calif., May 22, 2013 Early screening for prostate ... pregnancy testing is for women, thanks to UC Irvine ... American Chemical Society . , After more than a ... way to clearly identify clinically usable markers for prostate ... detected far sooner, with greater accuracy and at dramatically ...
Breaking Biology News(10 mins):Mechanism discovered which aids Legionella to camouflage itself in the organism 2UCLA life scientists present new insights on climate change and species interactions 2UCLA life scientists present new insights on climate change and species interactions 3UCLA life scientists present new insights on climate change and species interactions 4UCLA life scientists present new insights on climate change and species interactions 5UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3(Date:5/22/2013)... Rochester, NY (PRWEB) May 22, 2013 ... can now have access to Adapt Courseware’s new ... curriculum in an adaptive framework that responds based ... Adapt Courseware , the provider of comprehensive adaptive ... experience, is continuing to develop introductory level general ...
(Date:5/22/2013)... Jersey (PRWEB) May 22, 2013 Ethos ... gift card system, fit for the busy lifestyle of the ... select a design appropriate for the occasion, whether it is ... an apology note, or any other occasion. , Clients should ... Jersey spa gift card designs on the Ethos Spa’s ...
(Date:5/22/2013)... TheBeautyPlace.com features Toppik and Bosley hair fibers, two ... of thinning or balding hair. Hair loss treatments can be ... hair loss during this waiting period, one can use these ... alternative to hair transplant surgery in general. , Bosley ... extremely effective way to eliminate the appearance of balding and ...
(Date:5/22/2013)... NJ (PRWEB) May 22, 2013 The health ... In some states, up to twenty-seven percent of all ... all bankruptcies of private citizens in the U.S. are related ... also affects prescription drugs, meaning that many patients cannot afford ... even get them filled at all. That's why MedicationDiscountCard.com ...
(Date:5/22/2013)... NJ (PRWEB) May 22, 2013 Officials ... today that its cicada services are now in full ... year that the cicada cycle emerges. , “The ... the year that they will emerge, so we’re now ... they are well protected during the invasion,” said R. ...
Breaking Medicine News(10 mins):Health News:Adapt Courseware Releases Introduction to Sociology for Colleges and Universities Nationwide 2Health News:Adapt Courseware Releases Introduction to Sociology for Colleges and Universities Nationwide 3Health News:Ethos Spa Skin And Laser Center Has Launched Their Customizable Gift Certificates 2Health News:TheBeautyPlace.com Divulges Two Innovative Hair Loss Concealers on the Market Today: Bosley Hair Thickening Fibers and Toppik Hair Building Fibers 2Health News:Lyrica Discount Cards Now Available From MedicationDiscountCard.com 2Health News:Alliance Commercial Pest Control, Inc. Now Offering Cicada Protection Services 2[0] Adapt Courseware Releases Introduction to Sociology for Colleges and Universities Nationwide[0] Ethos Spa Skin And Laser Center Has Launched Their Customizable Gift Certificates[0] TheBeautyPlace.com Divulges Two Innovative Hair Loss Concealers on the Market Today: Bosley Hair Thickening Fibers and Toppik Hair Building Fibers[0] Lyrica Discount Cards Now Available From MedicationDiscountCard.com[0] Alliance Commercial Pest Control, Inc. Now Offering Cicada Protection Services
tkRNAicHTSEDEMA3TelaprevirMUSCProLindacIndibulinAVAXOrallyCethrinGynecologicAlchemixCyclosertSubsidiaries
Other Tags| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |